CASI Pharmaceuticals (CASIF) Short-term Investments (2021 - 2023)

CASI Pharmaceuticals has reported Short-term Investments for 3 years, with the latest figure at $12.0 million in Q4 2023.

• For the quarter ending Q4 2023, Short-term Investments rose 721.55% year-over-year to $12.0 million; the trailing twelve-month figure through Dec 2023 stood at $12.0 million (up 721.55% YoY), and the FY2023 full-year result was $12.0 million, up 721.55% from the prior year.
• Short-term Investments for Q4 2023 stood at $12.0 million, down from $19.9 billion in the prior quarter.
• The five-year high for Short-term Investments was $19.9 billion in Q2 2023, with the low at $1.5 million in Q4 2022.
• Historically, Short-term Investments has averaged $5.0 billion across 3 years, with a median of $10.9 million in 2021.
• Annual changes were most pronounced in 2022 — Short-term Investments slumped 85.18% — and 2023, when it soared 721.55%.
• CASI Pharmaceuticals' Short-term Investments stood at $9.9 million in 2021, then tumbled by 85.18% to $1.5 million in 2022, then soared by 721.55% to $12.0 million in 2023.
• The last three Short-term Investments figures came in at $12.0 million (Q4 2023), $19.9 billion (Q2 2023), and $1.5 million (Q4 2022), per Business Quant data.